The China Loophole
Newsweek US|June 16, 2023
Federal employees can invest in Chinese companies sanctioned by the U.S. through their government retirement plan. How could that happen?
VALERIE BAUMAN and DIDI KIRSTEN TATLOW
The China Loophole

MILLIONS OF FEDERAL EMPLOYEES CAN invest in Chinese companies sanctioned by the U.S. government via its flagship retirement plan-even though these companies have been branded a danger to national security or are accused of profiting from forced labor or other human rights abuses, a Newsweek investigation reveals.

Since June 2022, the federal government's employee retirement savings plan-the largest in the world with $720 billion in assets-has offered its 6.8 million members the option to invest some of their savings via a platform that gives them access to an additional 5,000 mutual funds beyond the plan's core funds. Some of the funds available through the portal have holdings in Chinese companies that are on at least nine U.S. government sanctions or watch lists, according to an exclusive analysis for Newsweek by Washington D.C.-based consulting firm Kilo Alpha Strategies, using data from the Coalition for a Prosperous America, a nonprofit that describes itself as a bipartisan coalition of farmers, ranchers, manufacturers and labor organizations that make and grow things in the U.S.

Among those companies are a leading developer of engines for fighter planes and turbines for naval ships, solar panel firms targeted for allegedly using forced labor by Uyghurs and others living in China's western Xinjiang region, as well as makers of surveillance systems seen as a threat to the U.S.

Denne historien er fra June 16, 2023-utgaven av Newsweek US.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra June 16, 2023-utgaven av Newsweek US.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA NEWSWEEK USSe alt
AMERICA'S BEST LOYALTY PROGRAMS 2025
Newsweek US

AMERICA'S BEST LOYALTY PROGRAMS 2025

LOYALTY PROGRAMS HAVE BECOME A CORNERSTONE of the modern shopping experience, offering perks and rewards designed to keep customers returning for more.

time-read
3 mins  |
February 21, 2025
Winning the Global Game
Newsweek US

Winning the Global Game

The U.S. holds more cards than China. Whether we keep our strategic advantage depends on how we play our hand

time-read
3 mins  |
February 21, 2025
Solar Power
Newsweek US

Solar Power

Scientists' creation of a record-breaking \"artificial sun\" brings nuclear fusion energy a step closer to being a commercial reality

time-read
2 mins  |
February 21, 2025
Trump vs. Deep State
Newsweek US

Trump vs. Deep State

The president and his efficiency chief Elon Musk have brought in a wave of policies affecting federal employees' jobs. Government workers spoke to Newsweek about the impact

time-read
6 mins  |
February 21, 2025
MAD ABOUT THE GIRL
Newsweek US

MAD ABOUT THE GIRL

AS RENÉE ZELLWEGER REPRISES THE ICONIC CHARACTER, BRIDGET JONES' CREATOR - AND MILLIONS OF FANS, COULDN'T BE HAPPIER

time-read
10+ mins  |
February 21, 2025
Armed and Dangerous
Newsweek US

Armed and Dangerous

A Ukrainian colonel reveals how North Korean soldiers compared with their Russian allies

time-read
4 mins  |
February 21, 2025
Patrick Gibson
Newsweek US

Patrick Gibson

WHEN YOU TAKE ON A ROLE THAT SOMEBODY ELSE MADE FAMOUS, IT'S not easy.

time-read
2 mins  |
February 21, 2025
The AI Will See You Now
Newsweek US

The AI Will See You Now

A light-hearted study into artificial intelligence's ability to perform cognitive tasks has raised questions around the roles of AI and doctors in health care

time-read
6 mins  |
February 21, 2025
Jasmin Savoy Brown
Newsweek US

Jasmin Savoy Brown

SHOWTIME'S YELLOWJACKETS IS REALLY TWO shows in one.

time-read
2 mins  |
February 21, 2025
BIOTECH: Blood, Sweat and Tears
Newsweek US

BIOTECH: Blood, Sweat and Tears

Nine years in the making, Truvian's quick tabletop blood test promises to deliver where Theranos famously couldn't

time-read
6 mins  |
February 14, 2025